Immunocore reports second quarter financial results and provides a business update
Immunocore reported Q2 2026 revenue of $115.9 million from KIMMTRAK, an 18% increase year-over-year, with the company swinging to a net profit of $0.02 per share compared to a $0.20 loss in the prior year. Enrollment in the pivotal Phase 3 TEBE-AM trial is nearing its target of 540 patients, with topline data potentially available by the end of 2026.
Key figures
- Revenue
- 115927000
- Revenue Yoy
- 18%
- Cash position
- 880200000
- Kimmtrak h1 revenue
- 222600000
- Kimmtrak q2 revenue
- 115900000
- Rd expenses q2 2026
- 73945000
- Phase 3 enrollment target
- 540
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.